Medicine and Health Sciences Commons^™

Identifying Barriers To Statin Therapy In Diabetic Patients In A Large Ambulatory Practice, Jennifer Moyer, Md, Rachel Ehrman-Dupre, Md, Andrew Rabovsky, Md, Simon Newsom, Md, Pooja Padgaonkar, Md, Julita Mitchell, Md, Sarah Hirsh, Md, Madeline Taskier, Md, Robert Wiley, Md, Lilli Flink, Md, Greta Bires, Md, Geoffrey Mills, Md

House Staff Quality Improvement and Patient Safety Conference (2020-)

Aim 1: To understand the root cause(s) for gaps in statin therapy within a large ambulatory care practice.

Aim 2: To improve provider awareness of indications for statin therapy, as recommended by the ACC/AHA guidelines.

Aim 3: To increase the proportion of patients with diabetes at our practice that are on statin therapy.

Renoprotective Effect Of Sglt-2 Inhibitors Vs ​ Ace Inhibitors In Type 2 Diabetes, Duncan Pickett

Capstone Showcase

Abstract

Introduction: Type 2 diabetes mellitus (DM2) is one of the most prevalent diseases worldwide today, and consistently growing over the years. The illness is marked by progressively increased insulin resistance in the body’s cells, leading to glucose overload, and eventually cell and organ damage and death. One end result of DM2 is nephropathy. The current first-line treatment for DM2 is a class of drugs called angiotensin-converting-enzyme inhibitors (ACE inhibitors). ACE inhibitors are considered reno-protective, but eventually nephropathy occurs in patients taking the drug regardless. This paper will address the efficacy of a new alternative diabetes drug, sodium-glucose cotransporter-2 inhibitors …